HK1147674A1 - Heterocyclic compounds as crth2 receptor antagonists crth2 - Google Patents

Heterocyclic compounds as crth2 receptor antagonists crth2

Info

Publication number
HK1147674A1
HK1147674A1 HK11101706.0A HK11101706A HK1147674A1 HK 1147674 A1 HK1147674 A1 HK 1147674A1 HK 11101706 A HK11101706 A HK 11101706A HK 1147674 A1 HK1147674 A1 HK 1147674A1
Authority
HK
Hong Kong
Prior art keywords
crth2
receptor antagonists
heterocyclic compounds
crth2 receptor
heterocyclic
Prior art date
Application number
HK11101706.0A
Other languages
English (en)
Chinese (zh)
Inventor
袁偉
Original Assignee
北京賽林泰醫藥技術有限公司
石藥集團中奇製藥技術
石家莊
有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 北京賽林泰醫藥技術有限公司, 石藥集團中奇製藥技術, 石家莊, 有限公司 filed Critical 北京賽林泰醫藥技術有限公司
Publication of HK1147674A1 publication Critical patent/HK1147674A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK11101706.0A 2007-10-10 2011-02-22 Heterocyclic compounds as crth2 receptor antagonists crth2 HK1147674A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99829807P 2007-10-10 2007-10-10
PCT/US2008/079303 WO2009049021A1 (fr) 2007-10-10 2008-10-09 Composés hétérocycliques sous forme d'antagonistes du récepteur crth2

Publications (1)

Publication Number Publication Date
HK1147674A1 true HK1147674A1 (en) 2011-08-19

Family

ID=40549546

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11101706.0A HK1147674A1 (en) 2007-10-10 2011-02-22 Heterocyclic compounds as crth2 receptor antagonists crth2

Country Status (13)

Country Link
US (1) US8772312B2 (fr)
EP (1) EP2197438B1 (fr)
JP (2) JP2011500584A (fr)
KR (2) KR101442663B1 (fr)
CN (1) CN101896178B (fr)
AU (1) AU2008310874B2 (fr)
BR (1) BRPI0815948A2 (fr)
CA (1) CA2700824C (fr)
ES (1) ES2548577T3 (fr)
HK (1) HK1147674A1 (fr)
IL (1) IL204823A0 (fr)
RU (1) RU2451019C2 (fr)
WO (1) WO2009049021A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011526281A (ja) 2008-06-24 2011-10-06 アミラ ファーマシューティカルズ，インク． プロスタグランジンｄ２受容体のシクロアルカン［ｂ］インドールアンタゴニスト
CA2737483A1 (fr) 2008-09-22 2010-03-25 Merck Frosst Canada Ltd. Derives d'indole comme antagonistes du recepteur crth2
US8546422B2 (en) * 2008-09-22 2013-10-01 Merck Canada Inc. Azaindole derivatives as CRTH2 receptor antagonists
GB2465062B (en) 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
AU2010256360A1 (en) 2009-06-05 2012-01-12 Astrazeneca Ab Aminopyrrolidinone derivatives and uses thereof
TWI562987B (en) 2010-03-22 2016-12-21 Actelion Pharmaceuticals Ltd 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
EP2457900A1 (fr) 2010-11-25 2012-05-30 Almirall, S.A. Nouveaux dérivés de pyrazole présentant un comportement antagoniste CRTH2
WO2012107364A1 (fr) * 2011-02-07 2012-08-16 Scipharm Sàrl Nouvelle composition de traitement de la mucoviscidose
EP2697223B1 (fr) 2011-04-14 2016-07-13 Actelion Pharmaceuticals Ltd. Dérivés d'acide 7-(hétéroaryl-amino)-6,7,8,9-tétrahydropyrido[1,2-a]indolacétique et leur utilisation en tant que modulateurs du récepteur aux prostaglandines d2
PL3119779T3 (pl) 2014-03-17 2019-01-31 Idorsia Pharmaceuticals Ltd Pochodne kwasu azaindolooctowego i ich zastosowanie jako modulatorów receptora prostaglandyny d2
JP6484644B2 (ja) 2014-03-18 2019-03-13 イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ アザインドール酢酸誘導体及びプロスタグランジンｄ２受容体調節剤としてのそれらの使用
JP6770522B2 (ja) * 2015-02-13 2020-10-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 全身性エリテマトーデスを予防し、及び／又は、治療するためのｐｔｇｄｒ−１及び／又はｐｔｇｄｒ−２アンタゴニスト
WO2017005759A1 (fr) * 2015-07-07 2017-01-12 Intervet International B.V. Procédé pour produire des dérivés d'azaindole
WO2017005764A1 (fr) * 2015-07-07 2017-01-12 Intervet International B.V. Procédé de production d'intermédiaires tricyclocétones d'antagonistes de crth2
MX2018003202A (es) 2015-09-15 2018-06-08 Idorsia Pharmaceuticals Ltd Formas cristalinas.
SI3356329T1 (sl) * 2015-09-29 2020-08-31 Novartis Ag Postopek priprave 1-(4-metansulfonil-2-trifluorometil-benzil)-2-metil- 1H-pirolo (2,3-b)piridin-3-il-ocetne kisline
JOP20190223A1 (ar) * 2017-04-01 2019-09-26 Novartis Ag عملية لتحضير حمض 1-(4- ميثان سلفونيل -2- تراي فلورو ميثيل - بنزيل)-2- ميثيل -1h- بيرولو [2، 3-b] بيريدين -3- يل- أسيتيك
CN113382995A (zh) * 2019-01-10 2021-09-10 石药集团中奇制药技术（石家庄）有限公司 作为crth2受体拮抗剂的杂环化合物的晶型
WO2020143793A1 (fr) 2019-01-10 2020-07-16 石药集团中奇制药技术（石家庄）有限公司 Sels de composé hétérocyclique et utilisation associée
CN114502164B (zh) * 2019-05-22 2024-01-26 石药集团中奇制药技术（石家庄）有限公司 杂环化合物及其盐的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1395590B1 (fr) 2001-05-23 2006-09-27 Merck Frosst Canada & Co. Derives de dihydropyrrolo¬1,2-a|indole et de tetrahydropyrido¬1,2-a|-indole utilises comme antagonistes des recepteurs de prostaglandine d2
CN1732171A (zh) * 2002-10-30 2006-02-08 麦克弗罗斯特(加拿大)公司 吡啶并吡咯里嗪和吡啶并吲嗪衍生物
WO2004039807A1 (fr) * 2002-10-30 2004-05-13 Merck Frosst Canada & Co. Pyridopyrrolizine et derives de pyridoindolizine
DK1725553T3 (da) * 2004-03-11 2008-08-18 Actelion Pharmaceuticals Ltd Tetrahydropyridoindolderivater
JP4708885B2 (ja) * 2005-07-06 2011-06-22 日本電気株式会社 符号化装置、携帯端末装置及びそれらに用いる画素色情報符号化方法
US7696222B2 (en) * 2005-08-12 2010-04-13 Merck Frosst Canada Ltd Indole derivatives as CRTH2 receptor antagonists
US20110112134A1 (en) * 2008-05-16 2011-05-12 Amira Pharmaceuticals, Inc. Tricyclic Antagonists of Prostaglandin D2 Receptors

Also Published As

Publication number Publication date
CN101896178A (zh) 2010-11-24
EP2197438A4 (fr) 2011-10-12
JP5680146B2 (ja) 2015-03-04
EP2197438B1 (fr) 2015-07-15
CA2700824C (fr) 2013-12-10
US20100222270A1 (en) 2010-09-02
JP2013209425A (ja) 2013-10-10
RU2451019C2 (ru) 2012-05-20
KR101442663B1 (ko) 2014-09-22
RU2010117156A (ru) 2011-11-20
BRPI0815948A2 (pt) 2019-09-24
WO2009049021A1 (fr) 2009-04-16
AU2008310874A1 (en) 2009-04-16
ES2548577T3 (es) 2015-10-19
JP2011500584A (ja) 2011-01-06
CN101896178B (zh) 2013-11-20
KR20100065398A (ko) 2010-06-16
KR20130069840A (ko) 2013-06-26
AU2008310874B2 (en) 2012-03-15
CA2700824A1 (fr) 2009-04-16
EP2197438A1 (fr) 2010-06-23
IL204823A0 (en) 2010-11-30
US8772312B2 (en) 2014-07-08

Similar Documents

Publication Publication Date Title
HK1147674A1 (en) Heterocyclic compounds as crth2 receptor antagonists crth2
HK1244694A1 (zh) 新穎的胰高血糖素受體拮抗劑
HRP20140384T1 (en) Indole derivatives as crth2 receptor antagonists
EP2346865A4 (fr) Dérivés d'indole comme antagonistes du récepteur crth2
EP2344497A4 (fr) Dérivés d'azaindole comme antagonistes du récepteur crth2
EP2342201A4 (fr) Dérivés d'indole utilisables en tant qu'antagonistes du récepteur crth2
ZA200909163B (en) Imidazole derivatives as ccr2 receptor antagonists
GB0722216D0 (en) Use of crth2 antagonist compounds
IL201112A0 (en) Thiazolidine derivatives as orexin receptor antagonists
GB0722203D0 (en) Use of CRTH2 antagonist compounds
EP1915372A4 (fr) Derives d'indole en tant qu'antagonistes du recepteur crth2
EP2215094A4 (fr) Composés hétérocycliques à teneur en n
EP2320906A4 (fr) Dérivés d amides hétérocycliques en tant qu antagonistes du récepteur ep4
ZA200800320B (en) Indol-3-carbonyl-spiro-piperidine derivatives as Via receptor antagonists
ZA201006830B (en) Heterocyclic compounds as adenosine receptor antagonist
IL198241A0 (en) Pyrazoline compounds as mineralocorticoid receptor antagonists
EP2161996A4 (fr) Antagonistes des récepteurs cgrp à base de carboxamide hétérocyclique
IL199430A0 (en) Crth2 antagonists
EP2378877A4 (fr) Dérivés d'imidazolinone en tant qu'antagonistes de récepteurs cgrp
ZA200808766B (en) Nitrated heterocyclic compounds as endothelin receptor antagonist
EP2153736A4 (fr) Antagoniste inédit du récepteur des leucotriènes
IL205949A0 (en) 3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists
EP2146712A4 (fr) Antagonistes des récepteurs du cgrp aryl hétérocycliques
EP2365748A4 (fr) Antagonistes imidazoisoindoles des récepteurs du neuropeptide s
ZA201002171B (en) 2-s-benzyl substituted pyrimidines as crth2 antagonists